Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer.
| Status: | Archived |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2010 |
| End Date: | August 2011 |
Open-label Study for an Exploration of Tumor Accumulation of the 18F Labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY94-9392 Following a Single Intravenous Administration of 300 MBq (Corresponding to
The study will be conducted as an open label, single-dose, explorative study with patients
with histologically proven cancer and, preferably, tumor positive lesions in previously
performed nuclear medicine imaging examinations.
The investigational drug will be given as a single administration in a dose of
BAY 94 9392 (300 MBq, +/- 10%). The total duration of the study for each patient will be
approximately 8 days.
The study will be conducted as an open label, single-dose, explorative study with patients
with histologically proven cancer and, preferably, tumor positive lesions in previously
performed nuclear medicine imaging examinations.
The investigational drug will be given as a single administration in a dose of BAY 94 9392 (300 MBq, +/- 10%). The total duration of the study for each patient will be
approximately 8 days.
We found this trial at
1
site
Click here to add this to my saved trials
